Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

ELDN 10.29.2024

Full Press ReleaseSEC FilingsOur ELDN Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
  • 12.11.2024 - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
  • 11.26.2024 - Eledon Works Toward Potential T1D Treatment

Recent Filings

  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.20.2024 - 8-K Current report

IRVINE, Calif.,Oct. 29, 2024(GLOBE NEWSWIRE) --Eledon Pharmaceuticals, Inc.(“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of$3.65per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of$3.649per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of$0.001per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately$85 million. All of the shares of common stock and pre-funded warrants in the offering are to be sold by Eledon. The offering is expected to close on or aboutOctober 30, 2024, subject to the satisfaction of customary closing conditions.

The financing includes participation from new and existing investors, includingBVF Partners LP,RA Capital Management, Frazier Life Sciences, Blue Owl Healthcare Opportunities, First Light Asset Management,Sphera Healthcare,Woodline Partners LP,Nantahala CapitalandT1D Fund: A Breakthrough T1D Venture.

Leerink Partnersis acting as sole book-running manager for the offering.Noble Capital Markets Inc.is acting as financial advisor.

Eledon currently intends to use the net proceeds from this offering to advance its pipeline and for working capital and general corporate purposes.

The offering is being made pursuant to a registration statement on Form S-3 (File No. 333-282260), previously filed with theSecurities and Exchange Commission(the “SEC”) onSeptember 20, 2024and declared effective onOctober 2, 2024. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and final prospectus supplement relating to the offering will be filed with theSECand available on the SEC’s website atwww.sec.gov. Copies of the preliminary prospectus supplement and final prospectus supplement and the accompanying prospectus, once available, may also be obtained by contactingLeerink Partners LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, Massachusetts02109, by telephone at (800) 808-7525, ext. 6105, or by email atsyndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc.is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. Eledon’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Eledon is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered inIrvine, California.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding Eledon’s expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. No assurance can be given that the offering will be completed on the terms described. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the final prospectus supplement and accompanying prospectus that will be included in the registration statement. Additional risks and uncertainties that could cause Eledon’s actual results to differ materially from the forward-looking statements contained herein are discussed in the company’s quarterly 10-Qs, annual 10-K, and other filings with theSEC, which can be found atwww.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com

Media Contact:

Jenna UrbanBerry & Company Public Relations(212) 253 8881jurban@berrypr.com

Source: Eledon Pharmaceuticals

Primary Logo

Source: Eledon Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com